Madrigal Pharmaceuticals (MDGL) Assets Average (2011 - 2026)

Madrigal Pharmaceuticals (MDGL) has 16 years of Assets Average data on file, last reported at $1.2 billion in Q1 2026.

• On a quarterly basis, Assets Average rose 21.97% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 21.97% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 36.79% from the prior year.
• Assets Average for Q1 2026 stood at $1.2 billion, down from $1.3 billion in the prior quarter.
• Over the last five years, Assets Average for MDGL reached as high as $1.3 billion in Q4 2025 and fell as low as $187.5 million in Q3 2022.
• Historically, Assets Average has averaged $715.0 million across 5 years, with a median of $861.4 million in 2024.
• Across the five-year window, Assets Average plunged 40.72% in 2022 and soared 302.1% in 2024, its largest moves.
• Year by year, Assets Average stood at $260.6 million in 2022, then soared by 68.55% to $439.3 million in 2023, then soared by 140.81% to $1.1 billion in 2024, then increased by 23.94% to $1.3 billion in 2025, then fell by 5.15% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.